Background Elderly patients with major depression have a poorer prognosis, are less
responsive to treatment, and show greater functional decline compared with younger …

Objective: About one-third of patients with depression fail to achieve remission despite
treatment with multiple antidepressants. This study compared the efficacy and safety of …

Background About one-third of patients with depression fail to achieve remission despite
treatment with multiple antidepressants and are considered to have treatment-resistant …

Objective: To evaluate long-term safety and efficacy of esketamine nasal spray plus a new
oral antidepressant (OAD) in patients with treatment-resistant depression (TRD). Methods …

Importance Approximately one-third of patients with major depressive disorder (MDD) do not
respond to available antidepressants. Objective To assess the efficacy, safety, and dose …

Importance Controlled studies have shown short-term efficacy of esketamine for treatment-
resistant depression (TRD), but long-term effects remain to be established. Objective To …

Abstract Background Esketamine nasal spray (Spravato) in conjunction with oral
antidepressants (ADs) is approved in the European Union, United States, and other markets …

Objective: Esketamine, the S-enantiomer of ketamine, was recently approved as a rapid-
acting intranasal therapy for depression and is currently under development for suicidality …

Patients with treatment-resistant depression (TRD) have higher rates of relapse and
pronounced decreases in daily functioning and health-related quality of life compared to …

Purpose/Background: Numerous health authority approvals of esketamine nasal spray,
combined with oral antidepressant, to treat depressive symptoms in adults with major …